Midazolam B. Braun (Midazolam Hydrochloride)

Midazolam binds to a specific site on the GABA‑A receptor complex, acting as a positive allosteric modulator. This increases the frequency of chloride channel opening when GABA binds, enhancing inhibitory neurotransmission, which produces sedation, anxiolysis, amnesia, muscle relaxation, and anticonvulsant effects.

The dose of Midazolam B. Braun is individualized by the prescribing clinician based on the patient’s age, weight, clinical condition, route of administration, and concurrent medications. No fixed regimen is provided here; the prescriber sets the appropriate dose and titration schedule.

Midazolam is classified as having an unknown pregnancy category because limited data are available. It should be used during pregnancy only if the potential therapeutic benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as the drug can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including cold‑chain where required), and any necessary import documentation.

Midazolam is a short‑acting benzodiazepine, offering rapid onset and relatively brief duration compared with agents such as diazepam or lorazepam. Its potency and ability to be administered via multiple routes (IV, IM, rectal) make it suitable for procedural sedation, whereas longer‑acting benzodiazepines are often preferred for chronic anxiety management.

Midazolam B. Braun should be stored refrigerated at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration.

Midazolam can be given intravenously, intramuscularly, or rectally, depending on the clinical situation. Intravenous injection provides the fastest onset, while intramuscular and rectal routes are used when IV access is unavailable or for specific procedural protocols. Administration must be performed by qualified personnel with appropriate monitoring.

The most serious risks include severe respiratory depression, apnea, profound hypotension, paradoxical reactions such as agitation, and rare anaphylactic responses. Continuous monitoring of respiratory and cardiovascular status is essential, especially when Midazolam is combined with other central nervous system depressants.

Midazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, those with severe respiratory insufficiency, or individuals with acute narrow‑angle glaucoma. Caution is also advised for patients with myasthenia gravis, severe hepatic impairment, or those taking interacting medications that could lead to excessive sedation.